Clinical trial
A Phase III, Multicenter, Double-blind, Active-Controlled, 52 Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
NCT01089790 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Multicenter, Double-blind, Active-Controlled, 52 Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 31, 2010
- Completion date
- Not reported
- Enrollment
- 141 (actual)
- Sites
- 149
Conditions
As the registry lists them; a condition with its own page is linked.